

For a More  
**Active Life**



**Orthocross™**

[www.klcbio.com.tr](http://www.klcbio.com.tr)

# What is ORTHOCROSS™

Each incention delivers highly purified cross linked hyaluronic acid to the human joint disorders such as osteoarthritis

- Orthocross™, is intended for the treatment of symptoms of human joint disorders such as osteoarthritis.
- Orthocross™, is indicated for viscoelastic replenishment or replacement of synovial fluid.
- Reduced joint pain and stiffness for up to 12 months



## Treatment With ORTHOCROSS™

The product should be administered according to the frequency determined by the physician, according to the recommended frequency decision, such as 6-8-12 months. The orthopaedist should decide on the number of injections.

### WHEN SHOULD YOU NOT TAKE ORTHOCROSS™ ?

- Orthocross™, should not be injected in patients with known sensitivity to any of the ingredients contained in product.
- Orthocross™, should not be injected in patients with pre-existing infections of the skin in the region of the intended injection site.
- Orthocross™, should not be administered to patients with known systemic bleeding disorders and known infection of the index joint and infected and inflamed joints.
- Orthocross™, may contain trace amounts of gram positive bacterial proteins so should not be administered patients with a history of such allergy




# WHAT IS OSTEOARTHRITIS (OA) OF THE KNEE?

- Osteoarthritis (OA) is known as the most common chronic disease of the cartilage. As the cartilage breaks down due to wear-and-tear and/or mechanical stress, it causes swelling, pain and inflammation, leading to extracellular matrix (ECM) loss.<sup>1</sup>
- Knee osteoarthritis (KOA) is a progressive joint disease that often involves intra- and per articular structures<sup>2</sup> and is considered pathology characterized by articular cartilage lesions, synovitis, subchondral sclerosis, and osteophytes<sup>3</sup>.
- Knee osteoarthritis (OA) is most often a slowly progressive joint disorder characterized by cartilage degeneration and inflammation<sup>4</sup>. Knee OA commonly results in knee pain and decreases patients' mobility (e.g. walking and stair climbing)<sup>5</sup>.
- The pain of osteoarthritis is usually related to activity. For osteoarthritis of the knee, activities such as climbing stairs, getting out of a chair, and walking long distances bring on pain. Morning stiffness usually lasts less than 30 minutes<sup>6</sup>. Patients often note that their knees "give way," a so-called instability symptom.



# Orthocross™



Content	2.5% High Purity Hyaluronic Acid	3.0% High Purity Hyaluronic Acid
HA Content	75 mg	90 mg
Volume	3 mL	3 mL

# WHAT IS THE RISK FACTORS FOR OSTEOARTHRITIS?

- Age is one of the most risk factors<sup>7</sup>
- Biological age-related changes in the joint structures<sup>7</sup>
- Female sex (knee OA)<sup>8</sup>
- Obesity (knee OA)<sup>8</sup>
- Previous knee injury (knee OA)<sup>8</sup>
- Knee malalignment (knee OA)<sup>9,10</sup>
- knee extensor muscle weakness (knee OA)<sup>11</sup>
- Cam deformity and mild dysplasia (especially in the middle aged (55–65 years), but not in the older population (older 65 years)) (hip OA)<sup>12</sup>
- Severe dysplasia (hip OA)



# REFERENCES

1. R. Altman, E. Asch, D. Bloch, G. Bole, D. Borenstein, K. Brandt, W. Christy, T.D. Cooke, R. Greenwald, M. Hochberg, et al., Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee, Diagn. Ther. Crit. Commit. Am. Rheum. Assoc. Arthritis Rheum. 29 (8) (1986) 1039-1049.
2. Lane NE, Brandt K, Hawker G, et al. OARSIFDA initiative: Defining the disease state of osteoarthritis. Osteoarthritis Cartilage 2011;19(5):478-82.
3. Su K, Bai Y, Wang J, et al. Comparison of hyaluronic acid and PRP intra-articular injection with combined intra-articular and intraosseous PRP injections to treat patients with knee osteoarthritis. Clin Rheumatol 2018;37(5):1341- 50.
4. Cheng OT, Souzdalnitski D, Vrooman B, Cheng J. Evidence-Based Knee Injections for theManagement of Arthritis. Pain Med (United States). 2012;13(6):740-753.
5. Guccione A, Felson D, Anderson J et al. The effects of specific medical conditions on the functional limitations of elders in the Framingham Study. American Journal of Public Health. 1994;84(3):351-358.
6. Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Arthritis Rheum 1986;29:1039-49.
7. Zhang Y, Jordan JM. Epidemiology of osteoarthritis. Rheum Dis Clin North Am 2008; 34: 515-29.
8. Silverwood V, Blagojevic-Bucknall M, Jinks C, Jordan JL, Protheroe J, Jordan KP. Current evidence on risk factors for knee osteoarthritis in older adults: a systematic review and meta
9. Brouwer GM, van Tol AW, Bergink AP, et al. Association between valgus and varus alignment and the development and progression of radiographic osteoarthritis of the knee. Arthritis Rheum 2007; 56: 1204-11.
10. Runhaar J, van Middelkoop M, Reijman M, Vroegindewij D, Oei EH, Bierma-Zeinstra SM. Malalignment: a possible target for prevention of incident knee osteoarthritis in overweight and obese women. Rheumatology (Oxford) 2014; 53: 1618-24.
11. Oiestad BE, Juhl CB, Eitzen I, Thorlund JB. Knee extensor muscle weakness is a risk factor for development of knee osteoarthritis. A systematic review and meta-analysis. Osteoarthritis Cartilage 2015;23: 171-77.
12. Gala L, Clohisy JC, Beaulé PE. Hip dysplasia in the young adult Bone Joint Surg Am 2016; 98: 63-73.

For a More  
Active Life



**KLC BİYOTEKNOLOJİ VE DIŞ TİCARET A.Ş.**

Work Center Plaza - Orta Mah. Marifet Sok.

No: 4 Kat: 1 Kartal / İSTANBUL

Telefon: +90 216 208 55 55

Web : [www.klcbio.com.tr](http://www.klcbio.com.tr)

E-mail: [info@klc.com.tr](mailto:info@klc.com.tr)

